FDA Expands Gene Therapy to Kids 2+, Offering $2.2M Cure for Sickle Cell
The FDA’s approval of Casgevy for children as young as two promises to shift pediatric sickle cell care from lifelong management to a one-time curative intervention, but raises urgent questions about cost, access, and health equity.